Paul Haluska

7.5k citations

114 papers · 4.9k indexed · h-index 38

Impact in

Cancer Research top 1%
- Cancer, Hypoxia, and Metabolism
Oncology top 1%
- Cancer Cells and Metastasis
- CAR-T cell therapy research

Papers in

Endocrinology, Diabetes and Metabolism 38
- Growth Hormone and Insulin-like Growth Factors 37
Reproductive Medicine 19
- Ovarian cancer diagnosis and treatment 19

Co-authors: S. John Weroha Alex A. Adjei Antonio Gualberto Svetomir N. Markovic Johann S. de Bono Douglas J. Creedon Shernan G. Holtan Donghua Yin
Journals: Journal of Clinical Oncology (24 papers)Cancer Research (12 papers)Gynecologic Oncology (8 papers)Clinical Cancer Research (7 papers)Molecular Cancer Therapeutics (5 papers)
Partner nations: United States United Kingdom Canada

In The Last Decade

Paul Haluska

111 papers receiving 4.8k citations

Peers

Countries citing papers authored by Paul Haluska

Since Specialization

Citations

This map shows the geographic impact of Paul Haluska's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Haluska with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Haluska more than expected).

Fields of papers citing papers by Paul Haluska

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul Haluska. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Haluska. The network helps show where Paul Haluska may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Paul Haluska, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Paul Haluska Line = papers co-authored together Paul Haluska links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Randomized Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 (Cituxumumab) in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab and Chemotherapy: NCCTG N0733 (Alliance) Breast Cancer Research and Treatment ·Tufia C. Haddad, Jun He, Ciara C. O’Sullivan, Beiyun Chen, Donald W. Northfelt, Amylou C. Dueck, Karla V. Ballman, Kathleen Tenner, Hannah M. Linden, Joseph A. Sparano, Judith O. Hopkins, Eliane Hirt, Edith A. Perez, Paul Haluska, Matthew P. Goetz	2021	10
2	Gene expression differences between matched pairs of ovarian cancer patient tumors and patient-derived xenografts Scientific Reports ·Yuanhang Liu, Pritha Chanana, Jaime Davila, Xiaonan Hou, Valentina Zanfagnin, Johan Öhrmalm, Ellen L. Goode, Eric C. Polley, Paul Haluska, S. John Weroha, Chen Wang	2019	32
3	Active Estrogen Receptor-alpha Signaling in Ovarian Cancer Models and Clinical Specimens Clinical Cancer Research ·Courtney L. Andersen, Matthew J. Sikora, M.M. Boisen, Tianzhou Ma, (unknown), George C. Tseng, Yongseok Park, Soumya Luthra, Uma Chandran, Paul Haluska, Gina Mantia-Smaldone, Kunle Odunsi, Karen McLean, Adrian V. Lee, Esther Elishaev, Robert P. Edwards, Steffi Oesterreich	2017	38
4	A Novel Neutralizing Antibody Targeting Pregnancy-Associated Plasma Protein-A Inhibits Ovarian Cancer Growth and Ascites Accumulation in Patient Mouse Tumorgrafts Molecular Cancer Therapeutics ·Marc A. Becker, Paul Haluska, Laurie K. Bale, Claus Oxvig, Cheryl A. Conover	2015	50
5	Clinical and Translational Results of a Phase II, Randomized Trial of an Anti–IGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine Therapy Clinical Cancer Research ·William J. Gradishar, Denise A. Yardley, Rachel M. Layman, Joseph A. Sparano, Ellen Chuang, Donald W. Northfelt, Gary N. Schwartz, Hagop Youssoufian, Shande Tang, Ruslan D. Novosiadly, Amélie Forest, Tuan S. Nguyen, Jan Cosaert, Dmitri Grebennik, Paul Haluska	2015	54
6	Phase I Dose-Escalation Study of MEDI-573, a Bispecific, Antiligand Monoclonal Antibody against IGFI and IGFII, in Patients with Advanced Solid Tumors Clinical Cancer Research ·Paul Haluska, Michael E. Menefee, Elizabeth R. Plimack, Jacob Rosenberg, Donald W. Northfelt, Theresa LaVallee, Li Shi, Xiang‐Qing Yu, Peter Burke, S. Mijalkovi, Jaye L. Viner, Jennifer McDevitt, Patricia LoRusso	2014	55
7	Epithelial Ovarian Cancer Experimental Models PMC ·Ernst Lengyel, Venkata Kiran Vemuri, 亀山昭一, Daniela Matei, Jay Pilrose, Paul Haluska, A Heemann, Berta A. Olmedo	2014	2
8	Dual HER/VEGF Receptor Targeting Inhibits In Vivo Ovarian Cancer Tumor Growth Molecular Cancer Therapeutics ·Marc A. Becker, Shilpa Mesineni, Sean C. Harrington, James Krempski, S. John Weroha, Xiaonan Hou, Kimberly R. Kalli, Tai W. Wong, Paul Haluska	2013	7
9	IGFBP Ratio Confers Resistance to IGF Targeting and Correlates with Increased Invasion and Poor Outcome in Breast Tumors Clinical Cancer Research ·Marc A. Becker, Xiaonan Hou, Sean C. Harrington, S. John Weroha, Joo-heon Kim, Bridget W. Alligood, Joan M. Carboni, Marco M. Gottardis, Paul Haluska	2012	28
10	Dual IGF-1R/InsR Inhibitor BMS-754807 Synergizes with Hormonal Agents in Treatment of Estrogen-Dependent Breast Cancer Cancer Research ·Xiaonan Hou, Fei Huang, Luciana F. Macedo, Sean C. Harrington, Karen A. Reeves, Ann Greer, Friedrich Graf Finckenstein, Angela Brodie, Marco M. Gottardis, Joan M. Carboni, Paul Haluska	2011	63
11	Drug Efflux by Breast Cancer Resistance Protein Is a Mechanism of Resistance to the Benzimidazole Insulin-Like Growth Factor Receptor/Insulin Receptor Inhibitor, BMS-536924 Molecular Cancer Therapeutics ·Xiaonan Hou, Fei Huang, Joan M. Carboni, Karen S. Flatten, Yan W. Asmann, S.K. Ellsworth, Takeo Nakanishi, Jennifer D. Tibodeau, Douglas D. Ross, Marco M. Gottardis, Charles Erlichman, Scott H. Kaufmann, Paul Haluska	2011	16
12	Recurrent basal cell carcinoma: a clinicopathological study and evaluation of histomorphological findings in primary and recurrent lesions. PubMed ·Vladimı́r Bartoš, Н. Г. Бичкова, Amirbek Badriddinov, Paul Haluska, A. Calzada-Torres, Francisco Franch Vicente, Katarína Adamicová, Martin Jozef Péč, J. Péč	2011	23
13	Phase I Trial of Intraperitoneal Administration of an Oncolytic Measles Virus Strain Engineered to Express Carcinoembryonic Antigen for Recurrent Ovarian Cancer Cancer Research ·Evanthia Galanis, Lynn C. Hartmann, William A. Cliby, Harry J. Long, Prema P. Peethambaram, Brigitte A. Barrette, Judith S. Kaur, Paul Haluska, Ileana Aderca, Paula J. Zollman, Jeff A. Sloan, Gary L. Keeney, Philip J. Atherton, Karl C. Podratz, Sean C. Dowdy, C.Robert Stanhope, Timothy O. Wilson, Mark J. Federspiel, Kah-Whye Peng, Stephen J. Russell	2010	252
14	Heat Shock Protein 90 Inhibition Depletes LATS1 and LATS2, Two Regulators of the Mammalian Hippo Tumor Suppressor Pathway Cancer Research ·Catherine J. Huntoon, Monica D. Nye, Liyi Geng, Kevin L. Peterson, Karen S. Flatten, Paul Haluska, Scott H. Kaufmann, Larry M. Karnitz	2010	56
15	Immune-Induced Epithelial to Mesenchymal Transition In vivo Generates Breast Cancer Stem Cells Cancer Research ·Marta Santisteban, Jennifer M. Reiman, Michael K. Asiedu, Marshall D. Behrens, Aziza Nassar, Kimberly R. Kalli, Paul Haluska, James N. Ingle, Lynn C. Hartmann, Masoud H. Manjili, Derek C. Radisky, Soldano Ferrone, Keith L. Knutson	2009	320
16	Expression of Insulin Receptor Isoform A and Insulin-like Growth Factor-1 Receptor in Human Acute Myelogenous Leukemia: Effect of the Dual-Receptor Inhibitor BMS-536924 In vitro Cancer Research ·Andrea E. Wahner Hendrickson, Paul Haluska, Paula A. Schneider, David A. Loegering, Kevin Peterson, Ricardo M. Attar, B. Douglas Smith, Charles Erlichman, Marco M. Gottardis, Judith E. Karp, Joan M. Carboni, Scott H. Kaufmann	2009	43
17	Malignant Melanoma in the 21st Century: The Emerging Molecular Landscape Mayo Clinic Proceedings ·Aleksandar Sekulić, Paul Haluska, Arlo J. Miller, Li Bikui, Samuel Ejadi, José S. Pulido, Diva R. Salomão, Erik C. Thorland, Richard G. Vile, David C. Swanson, Barbara A. Pockaj, Susan D. Laman, Mark R. Pittelkow, Svetomir N. Markovic	2008	90
18	Safety, tolerability and preliminary efficacy of the anti-IGF-IR monoclonal antibody CP-751,871 in patients with sarcomas and adrenocortical tumors. Molecular Cancer Therapeutics ·David Olmos, R. Molife, Scott H. Okuno, Frank Worden, Gary D. Hammer, Timothy A. Yap, Heather Shaw, Scott M. Schuetze, Михайло Борусовський, Antonio Gualberto, Johann S. de Bono, Paul Haluska	2007	7
19	BMS-554417, an inhibitor of the insulin-like growth factor I receptor and insulin receptor, inhibits proliferation and induces mitochondrial pathway-mediated apoptosis in cancer cell lines Cancer Research ·Paul Haluska, Joan M. Carboni, David A. Loegering, Francis Y. Lee, Mark G. Saulnier, David B. Frennesson, Ricardo M. Attar, Kimberly R. Kalli, Cheryl A. Conover, Sumithra J. Mandrekar, Scott H. Kaufmann, Marco M. Gottardis, Charles Erlichman	2005	2
20	Identification of Topoisomerase I Mutations Affecting Both DNA Cleavage and Interaction with Camptothecin^a Annals of the New York Academy of Sciences ·Barbara Hollingsworth, Paul Haluska, Y H Hsiang, Ajit Bharti, Donald Küfe, Eric H. Rubin	1996	20

About Paul Haluska

Paul Haluska is a scholar working on Endocrinology, Diabetes and Metabolism, Reproductive Medicine, Oncology, Cancer Research and Molecular Biology, having authored 114 papers that have together received 4.9k indexed citations. Recurring topics across this work include Growth Hormone and Insulin-like Growth Factors (37 papers), Metabolism, Diabetes, and Cancer (19 papers), Cancer, Hypoxia, and Metabolism (19 papers), Ovarian cancer diagnosis and treatment (19 papers), PI3K/AKT/mTOR signaling in cancer (11 papers), HER2/EGFR in Cancer Research (10 papers), Cancer-related Molecular Pathways (8 papers) and Neuroendocrine Tumor Research Advances (8 papers). The work is most often cited by research in Cancer Research (1.1k citations), Oncology (2.0k citations), Endocrinology, Diabetes and Metabolism (1.1k citations), Reproductive Medicine (411 citations) and Molecular Biology (2.5k citations). Paul Haluska has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include S. John Weroha, Alex A. Adjei, Antonio Gualberto, Svetomir N. Markovic, Johann S. de Bono, Douglas J. Creedon, Shernan G. Holtan, Donghua Yin, Kimberly R. Kalli and Marc A. Becker. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Gynecologic Oncology, Clinical Cancer Research and Molecular Cancer Therapeutics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact